Global Long-acting EPO Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Long-acting EPO Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Long-acting erythropoietin (EPO) drugs are a type of medication used to stimulate the production of red blood cells in the body. These drugs are primarily prescribed for individuals with certain medical conditions, such as anemia associated with chronic kidney disease or cancer treatment.
Global Long-acting EPO Drugs market is projected to reach US$ 1102.1 million in 2029, increasing from US$ 843 million in 2022, with the CAGR of 4.2% during the period of 2024 to 2029. Demand from Anemia and Kidney Disorders are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Long-acting EPO Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Long-acting EPO Drugs key manufacturers include Amgen, Johnson & Johnson and Kyowa Kirin, etc. Amgen, Johnson & Johnson, Kyowa Kirin are top 3 players and held % sales share in total in 2022.
Long-acting EPO Drugs can be divided into Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Others, etc. Epoetin-alfa is the mainstream product in the market, accounting for % sales share globally in 2022.
Long-acting EPO Drugs is widely used in various fields, such as Anemia, Kidney Disorders and Others,, etc. Anemia provides greatest supports to the Long-acting EPO Drugs industry development. In 2022, global % sales of Long-acting EPO Drugs went into Anemia filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Long-acting EPO Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Amgen
Johnson & Johnson
Kyowa Kirin
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Anemia
Kidney Disorders
Others
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Long-acting EPO Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Long-acting EPO Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Long-acting EPO Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Long-acting EPO Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Long-acting EPO Drugs introduction, etc. Long-acting EPO Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Long-acting EPO Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Global Long-acting EPO Drugs market is projected to reach US$ 1102.1 million in 2029, increasing from US$ 843 million in 2022, with the CAGR of 4.2% during the period of 2024 to 2029. Demand from Anemia and Kidney Disorders are the major drivers for the industry.
North America, Europe and Asia Pacific are the key regions for Long-acting EPO Drugs industry. Among those areas, stimulated by rigid demand from downstream industries, Asia Pacific is estimated to experience fast growth, with the CAGR of % during 2024 to 2029.
Globally, Long-acting EPO Drugs key manufacturers include Amgen, Johnson & Johnson and Kyowa Kirin, etc. Amgen, Johnson & Johnson, Kyowa Kirin are top 3 players and held % sales share in total in 2022.
Long-acting EPO Drugs can be divided into Epoetin-alfa, Epoetin-beta, Darbepoetin-alfa and Others, etc. Epoetin-alfa is the mainstream product in the market, accounting for % sales share globally in 2022.
Long-acting EPO Drugs is widely used in various fields, such as Anemia, Kidney Disorders and Others,, etc. Anemia provides greatest supports to the Long-acting EPO Drugs industry development. In 2022, global % sales of Long-acting EPO Drugs went into Anemia filed.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Long-acting EPO Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Amgen
Johnson & Johnson
Kyowa Kirin
Segment by Type
Epoetin-alfa
Epoetin-beta
Darbepoetin-alfa
Others
Segment by Application
Anemia
Kidney Disorders
Others
Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Long-acting EPO Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Long-acting EPO Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Long-acting EPO Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Long-acting EPO Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Long-acting EPO Drugs introduction, etc. Long-acting EPO Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Long-acting EPO Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.